GPGuido Pennings

Guido Pennings

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Guido Pennings has a total of 501 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sharing new genetic risk information with recipients of donor gametes

    by Dorian Accoe, Guido Pennings, Sandra Janssens, Frauke Vanden Meerschaut, Kelly Tilleman, Heidi Mertes

  • Open Access

    The attitude of (would-be) recipients of donor sperm and interested persons regarding a worldwide family limit per donor

    by Guido Pennings, Emilie Lassen, Anne-Bine Skytte

    Purpose This study assessed the attitudes of (would-be) recipients of donor sperm and interested persons toward worldwide donor family quota, ideal and acceptable family numbers, reasons for supporting or opposing limits, and willingness to pay for restricted donors. Methods A cross-sectional online survey was conducted between August and September 2025. Univariate and multinomial logistic regression analyses were performed to identify demographic predictors of attitudes toward a worldwide family limit. Results Overall, 70.3% of respondents supported a worldwide donor family quota, 21.6% opposed it, and 7.7% were uncertain. Support was significantly associated with older age, higher education, higher income, European residence, and being a mother of a donor-conceived child. In multinomial analyses, respondents in heterosexual relationships and those living outside Europe were significantly more likely to oppose a worldwide limit. The most frequently cited reason for supporting a limit was concern about accidental romantic relationships between donor half-siblings, followed by concerns about genetic disease transmission and psychosocial harm associated with large donor-sibling groups. Those opposing a worldwide limit most commonly cited reduced access to donor sperm, longer waiting times, and the absence of compelling reasons for a global cap. Five families was the most commonly preferred limit, whereas 15–25 families were more often considered acceptable. Willingness to pay increased as family limits decreased. Conclusion Most respondents supported a worldwide donor family limit, although the principal reasons cited—consanguinity and genetic disease risks—are not supported by current scientific evidence. Policymakers should balance concerns about large same-donor offspring groups against the potential consequences of stricter limits, including reduced access to donor sperm, higher costs, longer waiting times, and diminished reproductive choice.

  • The Implications of Reducing the Number of Families per Donor Worldwide

    by Guido Pennings

    Background: Many countries impose legal limits on the number of families that may be created using the sperm of a single donor, yet these limits vary widely and are not supported by robust empirical justification. The globalization of the sperm donation market and the widespread use of international commercial sperm banks may potentially result in (very) large international groups of same‐donor offspring. Objectives: The study intended to find out which ethical, psychosocial, and regulatory concerns, including risks of consanguinity, genetic disorders, and the impact on donor‐conceived persons, follow from these developments. While there are increasing calls to establish a worldwide family limit per donor, the consequences of such a policy for the availability, accessibility, and affordability of donor sperm remain unclear. Methods: This paper examines empirical data on donor use, donor types, and supply–demand dynamics in several jurisdictions. A search has been made of all available databases to find recent and relevant data on the average number of offspring per donor, differences in donor type, and effects of allowing donor selection by recipients. Results: The predicted negative effects of a global family limit on sperm supply depend largely on the level at which the limit is set. The analysis further suggests that current inefficiencies are partly driven by recipient choice and reliance on foreign donors. Although restricting donor selection and importation could improve efficiency, such measures would reduce recipient autonomy. Conclusions: Overall, the impact of a mandatory European or global family limit is highly context‐dependent, but low limits would significantly affect sperm availability and constrain recipient choice.


  • Open Access

    Delayed reproduction: A small step in the right direction

    by Guido Pennings

    The predicted global population increase, despite declining fertility rates in many countries, poses a serious threat by adding to overpopulation, resource depletion and climate change. This paper supports trends that contribute both to ethically valuable goals such as justice and autonomy, and to reduced fertility rates. The primary focus is on universal women’s education as the means to promote both reproductive autonomy and climate mitigation. Delayed reproduction is one consequence of increased women’s education and should also be welcomed. In order to effectively promote reproductive autonomy, it is essential to challenge the widespread pronatalist ideology. This pervasive ideology influences reproductive intentions and undermines autonomy. Delayed parenthood should not be framed as a restriction, but rather as an empowering consequence of greater educational and economic opportunities for women. Ultimately, supporting social trends like delayed fertility can align ethical, environmental and demographic goals without infringing on personal freedom.


  • Risk management and the further use of gametes from a donor with a known pathogenic variant

    by Dorian Accoe, Guido Pennings, Sandra Janssens, Heidi Mertes

    Some donor-conceived persons are born with an autosomal recessive genetic condition. In response, some fertility clinics categorically restrict the further use of the gametes from the donor who transmitted the pathogenic variant, although the chance of recurrence is usually very low. The level of specific risk that a recipient or physician is willing to accept depends on various factors, including severity, lived experiences and personal preferences. However, on a policy level, we argue for consistency and guidance on the principled question of whether the (further) use of gametes from donors who are carriers of a known pathogenic variant with autosomal recessive inheritance is acceptable. Provided that the identified risk is comparable to the general risk of genetic conditions, the continued use of the donor gametes can remain an acceptable option.

  • Top Cited Papers
    Open Access

    Recommendations from the WHO guideline for the prevention, diagnosis, and treatment of infertility

    by Gitau Mburu, Nancy Santesso, Romina Brignardello-Petersen, Richard Kennedy, Cynthia Farquhar, Jacky Boivin, Guido Pennings, Linda C. Giudice, Robert W. Rebar, Luca Gianaroli, et al.


  • Top Cited Papers
    Open Access

    Recommendations from the WHO guideline for the prevention, diagnosis, and treatment of infertility

    by World Health Organisation Guideline Development Group for Infertility, Gitau Mburu, Nancy Santesso, Romina Brignardello-Petersen, Richard Kennedy, Cynthia Farquhar, Jacky Boivin, Guido Pennings, Linda C Giudice, Robert W Rebar, et al.

    STUDY QUESTION: What is the recommended prevention, diagnosis, and treatment of infertility among individuals and couples? SUMMARY ANSWER: The World Health Organization (WHO) made 40 recommendations and six good practice statements for the prevention, diagnosis, and treatment of infertility. WHAT IS KNOWN ALREADY: The field of sexual and reproductive health care, including family planning has progressed in the last several decades. Significant progress has also been made in the field of medically assisted reproduction. Globally, one in six people experience infertility in their lifetime. However, many countries do not include the prevention, diagnosis, and treatment of infertility in health policies, financing, and services, and many do not have national clinical guidelines for the prevention, diagnosis, and treatment of infertility. STUDY DESIGN, SIZE, DURATION: The guideline was developed according to the WHO handbook for guideline development. A Guideline Development Group (GDG) was assembled and included a multidisciplinary and regionally diverse set of clinicians, policymakers, researchers, implementers, and representatives of patient groups (n=30). The GDG prioritized key recommendation questions to address in the guideline. PARTICIPANTS/MATERIALS, SETTING, METHODS: New systematic reviews were conducted, or existing reviews updated, to inform the recommendations. The GRADE approach was used to assess the certainty of the evidence and to guide the formulation of recommendations. The GDG interpreted evidence and made judgments about the balance between benefits and harms (including patients’ values) as well as costs, feasibility, acceptability, and equity. The recommendations were drafted, reviewed by an External Review Group (ERG) comprising 30 members, and approved by the WHO. MAIN RESULTS AND THE ROLE OF CHANCE: The guideline makes good practice statements related to the general management of infertility (n = 6) including (i) selection of tests, (ii) listening to individuals and couples with infertility, (iii) choosing treatment decisions, (iv) clinical follow-up, and (v) documenting outcomes of treatment. In relation to prevention, it provides recommendations related to the provision of information about fertility and infertility (n = 1) and reduction of infertility risk from sexually transmitted infections (STIs; n = 1), lifestyle factors (n = 1), and tobacco use (n = 1). In terms of diagnosis, recommendations for diagnosing infertility caused by ovulatory dysfunction (n = 3), tubal disease (n = 1), or uterine cavity abnormalities (n = 5) among females are provided. For males, the guideline provides recommendations regarding when a semen test should be repeated (n = 2). Also included is a recommendation for diagnosing unexplained infertility (n = 1). Regarding treatment, the guideline provides recommendations related to the treatment of polycystic ovary syndrome (n = 6), tubal disease (n = 5), uterine septae (n = 1), varicocele (n = 4), and unexplained infertility (n = 6). Based on available evidence, the GDG did not make a recommendation for or against the use of antioxidant supplements in males. Most recommendations were conditional because relevant evidence was either absent, or of low or very low certainty. Critical research gaps were identified. LIMITATIONS, REASONS FOR CAUTION: The recommendations do not cover all aspects of infertility and fertility care, but subsequent editions of the guideline will expand the scope of recommendations. WIDER IMPLICATIONS OF THE FINDINGS: By centring equity, science, and the imperative to provide fertility care as part of universal health coverage, the guideline aims to support countries in delivering high-quality, equitable, and effective healthcare for all. Although the guideline is primarily intended for use by health care professionals, it is an important source for policymakers to inform national guidelines and to inform the work of professional patient support, including advocacy organizations, funding and philanthropic agencies, civil society, professional societies, and other nongovernmental organizations that provide social, financial, and technical support to reproductive health programmes. STUDY FUNDING/COMPETING INTEREST(S): This work received funding from the UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), a cosponsored programme executed by the World Health Organization (WHO). Full details of declared interests of all named authors are shown in Supplementary Table S1, those for members of the GDG who are not named authors are shown in Supplementary Table S2 and those for members of the ERG are shown in Supplementary Table S3. TRIAL REGISTRATION NUMBER: N/A. DISCLAIMER: This manuscript reports a summary of recommendations from a WHO guideline. All reasonable precautions have been taken by WHO to verify the information contained in the guideline publication. However, the published material is being distributed without warranty of any kind, either expressed or implied.


  • Non-identity problem and the ‘all-things-considered’ moral obligation to have genetically related children

    by Guido Pennings

    Dr Marcus Teo states that my claim that prospective parents have a moral obligation to have genetically related children is invalid because I have ignored the non-identity problem. He maintains that donor-conceived persons (DCPs) cannot be harmed by their conception, as they would not exist otherwise. However, an analysis of his argument shows that the reason why he does not recognise such moral obligation is not the non-identity problem but his rejection of the Principle of Procreative Beneficence. He instead adopts a ‘minimal threshold’ principle: as long as a child’s life is worth living, there is no obligation to select the child with the best possible life. Teo also claims that my article may cause unnecessary anxiety in parents. However, these concerns have mostly been raised by psychological professionals who have highlighted the complexities of donor conception. Nevertheless, to address these concerns, the original claim could be refined into an ‘all-things-considered’ moral obligation, which would acknowledge more explicitly that it can be overridden by stronger moral reasons. Talbot et al state that my conclusion regarding the future well-being of DCPs is premature and based on selective evidence. However, their literature review does not contradict my claim that a substantial number of DCPs experience negative psychosocial effects. Societal trends such as ancestry testing and increasing focus on genetic ties may worsen these outcomes in the future.

  • Identifying essential information for a valid informed consent of egg donors: an international Delphi study

    by L Jacxsens, G Pennings, L Lentacker, D Stoop, V Provoost

    STUDY QUESTION: What information does an international group of professionals and egg donors consider relevant and morally necessary for prospective egg donors to provide valid informed consent? SUMMARY ANSWER: Participants considered 80% of all concrete information items (CIIs) to be relevant (e.g. all legal aspects) and 67% to be morally necessary. WHAT IS KNOWN ALREADY: Studies indicate that egg donors are not always adequately informed and have expressed a desire for more comprehensive information. This highlights the need for a comprehensive guideline of essential information for prospective egg donors. STUDY DESIGN, SIZE, DURATION: This modified Delphi study used a survey in an iterative process of three rounds to reach a consensus on what information items are relevant and morally necessary for a valid informed consent of candidate egg donors. Invitations to participate were sent out in November 2023 and the final round closed in November 2024. PARTICIPANTS/MATERIALS, SETTING, METHODS: The 35 participants were experienced egg donors and professionals from a range of disciplines (social and medical sciences, bioethics, psychology, fertility medicine and law) from 14 countries. The survey consisted of 13 categories and 133 CIIs, which participants scored for relevance via a 4-point Likert scale and moral necessity on a dichotomous scale (yes/no). Content Validity Index (CVI) was calculated for measuring relevance and percentage of agreement for moral necessity. A comment section was available. MAIN RESULTS AND THE ROLE OF CHANCE: Consensus was indicated as an I-CVI (CVI per item) of 0.78 or higher. The same cut-off was used to indicate consensus for moral necessity. For 27 out of 133 CIIs, the I-CVI was lower than 0.78. The percentage of moral necessity was below 0.78 for 44 CIIs. Four CIIs reached a I-CVI of 1: all experts thought it was relevant for a candidate donor to know (i) the need to undergo ovarian stimulation and (ii) a retrieval procedure, as well as (iii) her legal rights over the donated eggs after the retrieval procedure and (iv) her legal right to withdraw consent. The latter is the only CII that scored 100% on moral necessity. The CII with the lowest I-CVI is ‘The family type and characteristics of the potential recipients of the donor eggs’ (0.32). The CII with the lowest percentage of agreement for moral necessity was ‘An egg donor’s social circle might give negative feedback/opinions on the donation’ (36.36%). In several categories (e.g. ‘Physical side-effects and risks’), almost all CIIs reached a consensus among experienced egg donors, bioethicists, and humanities and social sciences experts, while hardly any CII reached a consensus among fertility experts, lawyers, and academic medical doctors. LIMITATIONS, REASONS FOR CAUTION: Despite our efforts, we were unable to obtain input from registered nurses and midwives. Not all participants remained engaged through all the iterative rounds, which may weaken the results of the study. However, the dropout rates between rounds in this study were within the acceptable 20–30% range. WIDER IMPLICATIONS OF THE FINDINGS: Our results give fertility professionals a standard of essential information to make sure that prospective egg donors are adequately informed and know what to expect when they decide to donate. It also gives researchers a potential standard to evaluate the quality of the information provision in fertility clinics. STUDY FUNDING/COMPETING INTEREST(S): This study is funded by the Special Research Fund, Bijzonder Onderzoeksfonds of Ghent University (BOFSTG2020000901). The authors declare that they have no competing interests. TRIAL REGISTRATION NUMBER: N/A.